CardioSurgeon.co.uk
The tricuspid valve is one of the heart’s four essential valves, responsible for regulating blood flow between the right atrium and right ventricle. It ensures that oxygen-poor blood moves efficiently in the correct direction, supporting the heart’s role in sending blood to the lungs for oxygenation. Tricuspid valve disease occurs when this valve does not function properly (either becoming narrowed (stenosis), leaky (regurgitation), or structurally abnormal). Think of the heart as a two-step pump on the right side. The right atrium is the first chamber in that process; it receives oxygen-poor blood returning from the body. It then passes that blood through the tricuspid valve into the right ventricle, which is responsible for pumping blood to the lungs. The right ventricle is less muscular than the left because it only needs to send blood a short distance to the lungs, where carbon dioxide is removed and oxygen is added.
Tricuspid valve disease most commonly involves the valve becoming leaky – tricuspid valve regurgitation, which accounts for about 90% of cases, while narrowing of the valve – tricuspid valve stenosis, is much less common. When the tricuspid valve doesn’t close properly and leaks, blood can flow backward into the right atrium instead of moving forward to the lungs. This creates a build-up of pressure in the heart and in the veins that return blood from the body, which can lead to swelling in the legs, abdomen, or liver (similar to a “traffic jam” in your circulation). At the same time, less blood reaches the lungs to pick up oxygen, so you may feel tired or notice reduced ability to exercise.
In some cases, the tricuspid valve may become leaky because of wires (called leads) from a pacemaker or defibrillator that pass through the valve. These leads are placed inside the heart to help control its rhythm, but as they cross the tricuspid valve, they can sometimes interfere with how it opens and closes. For example, a lead may prevent the valve leaflets from meeting properly, or it can become caught or “trapped” between them. When this happens, the valve cannot form a tight seal, allowing blood to leak backward into the right atrium. This type of leak is known as device-related tricuspid regurgitation. Doctors can usually identify this on heart scans and will take it into account when deciding on the best treatment, which may include adjusting the lead, managing symptoms, or, in some cases, considering procedures to repair the valve.
Tricuspid valve regurgitation can sometimes be caused by tricuspid valve endocarditis, which is an infection of the valve. This infection can damage the tricuspid valve leaflets, making them unable to close properly and leading to leakage. Endocarditis is more likely to occur in certain situations, such as in people with intravenous lines, implanted devices, or a history of intravenous drug use. Symptoms may include fever, tiredness, breathlessness, or signs of infection, along with swelling due to the leaking valve. Treatment usually involves a course of strong antibiotics to clear the infection, and in some cases, surgery may be needed to repair or replace the damaged valve. Early diagnosis and treatment are very important to prevent further complications and protect heart function.
Doctors assess how serious a tricuspid valve problem is by combining what they find during a physical examination with detailed imaging of the heart, most commonly an ultrasound scan called an echocardiogram. This scan shows how well the valve is opening and closing, how blood is flowing through the right side of the heart, and whether the right ventricle is under strain. In many cases, you may also need a transoesophageal echocardiogram (TOE). This is a specialised scan where a small ultrasound probe is passed gently down the food pipe (oesophagus), which sits directly behind the heart. Because of this close position, it provides much clearer and more detailed images of the tricuspid valve, helping doctors understand its structure and movement more precisely and plan the most appropriate treatment.
To guide care, tricuspid valve disease is grouped into four stages. Stage A (at risk) means there are risk factors (such as other heart conditions or raised pressure in the lungs) but the valve is still working normally. Stage B (progressive) refers to mild or moderate leakage that needs regular monitoring over time. Stage C (asymptomatic severe) means the valve problem is severe, even if you feel well, and there may already be early effects on the right side of the heart, such as enlargement or reduced efficiency. Stage D (symptomatic severe) is when the condition is advanced and causing symptoms like swelling, fatigue, or breathlessness, and treatment is usually recommended. This structured approach helps doctors decide the right time to act, ideally before long-term damage to the heart or circulation develops.
Surgery for isolated tricuspid valve disease is less common than for other heart valves, but it is performed when needed. The timing of this operation is very important. Doctors aim to intervene before the right ventricle (the heart’s pumping chamber on the right side) becomes too weak or enlarged. If surgery is delayed until the heart has already started to fail, the risks of the operation increase significantly. More importantly, the heart may lose its ability to recover and return toward a more normal size and function (a process known as positive remodelling). For this reason, careful monitoring and timely decision-making are essential to achieve the best possible outcome. Tricuspid valve surgery usually takes about 3–4 hours, and most people stay in hospital for around 5–7 days to recover. The surgeon may reach the heart through the breastbone or, in some cases, through a smaller cut. During the operation, a heart-lung machine temporarily takes over the job of the heart so the valve can be repaired or replaced safely. For some patients, a minimally invasive (keyhole) approach may be possible, using a small cut through the sternum (breast bone) or between the ribs. This can mean smaller scars, less discomfort, and a quicker recovery. However, it’s not suitable for everyone. Your doctor will discuss the best and safest option for you and support you throughout your treatment and recovery.
Tricuspid valve surgery is most commonly performed at the same time as other heart operations—this is known as concomitant tricuspid valve surgery and accounts for over 90% of tricuspid valve procedures. It is often done during mitral valve surgery, but may also be carried out alongside aortic valve, aortic aneurysm operations or any other heart operation. In the vast majority of cases, the tricuspid valve is repaired (rather than replaced), as the fundamental problem is regurgitation (leaking). The decision to repair the valve is sometimes made before surgery, based on scans and your overall condition. However, in some situations, the final decision is made during the operation, if the team believes it will improve how your heart works, reduce risks, and support a better recovery. This is carefully assessed using detailed imaging during surgery (called transoesophageal echocardiography) and involves close teamwork between the surgeon, anaesthetist, imaging specialist, and often cardiologists. The aim is always to choose the safest and most effective approach for your long-term heart health.
The preferred treatment for tricuspid valve disease is to repair the valve rather than replace it, whenever possible. Repairing the valve has several advantages, including better long-term survival, avoiding the need for lifelong blood-thinning medication, and preserving the heart’s natural function. In most cases (around 85–90%), the repair involves placing a supportive ring—called an annuloplasty ring—around the valve. This helps restore its shape and allows it to close properly. In a smaller number of cases (10–15%), additional techniques may be needed, such as using fine stitches (sometimes called artificial chords) or other repair sutures to support or reshape the valve leaflets.
If the leak is caused by a pacemaker or defibrillator lead passing through the valve, the lead may need to be carefully repositioned or removed before the repair is carried out. Your surgical team will assess this in detail to ensure the best and safest result.
Biological valves (also called tissue valves) are often used when the tricuspid valve needs to be replaced. These valves are usually made from cow or pig tissue and are specially treated to work safely inside the heart. One of their main advantages is that they have a low risk of forming blood clots, which means most patients do not need to take long-term blood-thinning medication. This makes them a convenient and safer option for many people, particularly if blood thinners are not suitable.
The main drawback is that biological valves do not last forever. Over time, they can gradually wear out and may need to be replaced again in the future. How long they last can vary, but they often function well for many years. Your doctor will discuss whether a biological valve is the right choice for you, taking into account your age, lifestyle, and overall health, to ensure the best long-term outcome.
Mechanical heart valves are very durable and designed to last a lifetime, as they are made from strong carbon-based materials that do not wear out. However, they can increase the risk of blood clots forming on their surface, so patients need to take lifelong blood-thinning medication to keep the valve working safely.
Mechanical valves are not commonly used in the tricuspid position. This is because blood flow on the right side of the heart is naturally slower and under lower pressure than on the left side, which increases the tendency for blood clots to form on artificial surfaces. Studies and clinical experience have shown that mechanical tricuspid valves have a higher risk of valve thrombosis (clot formation) compared with valves on the left side of the heart. To reduce this risk, patients often need more intensive blood thinning (a higher INR level) than usual, which in turn increases the risk of bleeding complications. Your doctor will take all of these factors into account when recommending the most appropriate treatment for you.
Percutaneous tricuspid valve repair using devices such as edge-to-edge repair systems like the TriClip, is a minimally invasive treatment option that can help reduce symptoms and improve quality of life in selected patients with tricuspid regurgitation. This treatment is usually offered to patients who are not suitable for open-heart surgery. This may be due to factors such as older age, frailty, multiple medical conditions (for example lung or kidney disease), previous heart surgeries, or a higher overall risk of complications from conventional surgery. It is typically performed under local anesthesia with sedation or general anesthesia, allowing for a faster recovery compared to open-heart surgery. During the procedure, a thin, flexible tube (catheter) is inserted through a vein in the leg (usually the femoral vein) and guided up to the heart. With the help of advanced imaging techniques, the doctor carefully positions and deploys the repair device on the tricuspid valve. The device works by bringing the valve leaflets closer together, improving their ability to close properly and thereby reducing backward blood flow (regurgitation).
Most individuals experience a relatively quick recovery and may be discharged within a day or two. Currently, this treatment is primarily offered to patients who are considered high risk for conventional surgery or are not suitable candidates for open-heart procedures.
Looking Ahead: Percutaneous Tricuspid Valve Implantation
In addition to repair techniques, less invasive tricuspid valve implantation procedures are also being developed. These approaches aim to place a new biological valve inside the existing tricuspid valve using a catheter (a thin, flexible tube), without the need for open-heart surgery. The new valve is supported by a small metal frame (stent) that helps it stay securely in position and function effectively. These procedures are still being studied and are not yet widely available. However, early results are encouraging, and they may offer an alternative treatment option in the future (especially for patients who are not suitable for surgery or for whom valve repair is not appropriate). Ongoing research and clinical trials continue to improve these techniques and assess their long-term safety and benefits.
